CSIMarket Company Name, Ticker, Customers, else..
 

Essa Pharma inc   (NASDAQ: EPIX)

Essa Pharma Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

EPIX Sales vs. its Competitors Q3 2025


Comparing the current results to its competitors, Essa Pharma Inc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 34.44 %, recorded in the same quarter.

• List of EPIX Competitors





Revenue Growth Comparisons




Net Income Comparison

Essa Pharma inc recorded a net loss, as well as most of its competitors.

<<  EPIX Stock Performance Comparisons


Essa Pharma Inc 's Comment on Competition and Industry Peers


The prostate cancer market is characterized by intense competition among companies with substantial financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Mergers and acquisitions have led to resource concentration among fewer competitors. Several pharmaceutical therapies are approved and available, with new molecules under investigation. Approved therapies and their manufacturers include Enzalutamide (Xtandi) by Astellas and Pfizer; Abiraterone acetate (Zytiga) by Johnson & Johnson; Abiraterone acetate (Yonsa) by Sun Pharma; Sipuleucel-T (Provenge) by Valeant; Docetaxel and Cabazitaxel by Sanofi; Olaparib/abiraterone acetate (Akeega) by Johnson & Johnson; and Talazaparib (Talzenna) by Pfizer. Generic versions of Zytiga are also approved and commercially available in the U.S. ESSA considers its competitive position strong due to its product candidate's unique mechanism targeting androgen receptor activation, which may circumvent resistance pathways associated with existing hormone-related therapies. Competitors identified include Astellas, Johnson & Johnson, Pfizer, Sanofi, Sun Pharma, and Valeant.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Essa Pharma inc




Aptevo Therapeutics Inc
Share Performance



-79.78%
This Year
Aptevo Therapeutics Inc
Profile

Aptevo Therapeutics Inc operates as a biotechnology company that focuses on the development of novel oncology and hematology therapeutics. The company primarily generates revenue through the sale of its products and potential collaborations with other pharmaceutical companies.

More about Aptevo Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.271 mill. $ - mill. $ -26.505 mill.


Phio Pharmaceuticals Corp
Share Performance



-3.70%
30 Days
Phio Pharmaceuticals Corp
Profile

Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.

More about Phio Pharmaceuticals Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 12.082 mill. $ - mill. $ -12.904 mill.


Cns Pharmaceuticals Inc
Share Performance



+14.37%
30 Days
Cns Pharmaceuticals Inc
Profile

CNS Pharmaceuticals Inc's business model focuses on developing innovative solutions and treatments for central nervous system diseases.

More about Cns Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 39.184 mill. $ - mill. $ -16.699 mill.


Bolt Biotherapeutics Inc
Share Performance



-2.95%
Over The Past 5 Days
Bolt Biotherapeutics Inc
Profile

Bolt Biotherapeutics Inc's business model focuses on developing novel immunotherapies for the treatment of cancer.

More about Bolt Biotherapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6.390 mill. $ 4.700 mill. $ -28.739 mill.


Nextcure Inc
Share Performance



-43.60%
This Year
Nextcure Inc
Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 39.770 mill. $ - mill. $ -42.748 mill.

60 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Essa Pharma inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Essa Pharma inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.